Geron Co. (NASDAQ:GERN) Sees Significant Decrease in Short Interest

Geron Co. (NASDAQ:GERN) saw a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 46,660,000 shares, a decline of 8.4% from the March 15th total of 50,950,000 shares. Based on an average trading volume of 11,240,000 shares, the short-interest ratio is presently 4.2 days.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Pathstone Family Office LLC acquired a new stake in shares of Geron during the third quarter worth $26,000. Cerity Partners LLC bought a new stake in shares of Geron in the fourth quarter valued at about $26,000. Creative Planning acquired a new position in shares of Geron during the third quarter worth about $26,000. CIBC Asset Management Inc bought a new position in shares of Geron during the fourth quarter worth about $27,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Geron by 101.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 6,757 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Trading Up 3.8 %

Geron stock traded up $0.13 during mid-day trading on Tuesday, hitting $3.58. 6,438,857 shares of the company’s stock were exchanged, compared to its average volume of 11,327,157. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $4.05. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $1.96 billion, a P/E ratio of -10.85 and a beta of 0.61. The company’s 50 day simple moving average is $2.64 and its 200-day simple moving average is $2.20.

Geron (NASDAQ:GERN) last released its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01. Geron had a negative return on equity of 63.33% and a negative net margin of 77,691.14%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. During the same quarter last year, the firm posted ($0.10) earnings per share. Geron’s revenue was down 77.7% compared to the same quarter last year. On average, equities analysts anticipate that Geron will post -0.34 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Geron in a research report on Thursday, April 11th. Wedbush restated an “outperform” rating and set a $6.00 target price on shares of Geron in a research report on Wednesday, April 10th. Finally, The Goldman Sachs Group increased their price target on shares of Geron from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Friday, March 15th.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.